Thursday, April 13
8:00 am NYC | 2:00 pm Cape Town/Geneva | 5:30 pm New Delhi | 7:00 pm Jakarta
Ending the tuberculosis (TB) epidemic will require developing and deploying new safe, effective, and affordable TB vaccines, and the next few years will be a decisive chapter in this unfolding story. Much of the excitement has centered on a vaccine candidate called M72/AS01E, which is expected to begin a phase III efficacy trial later this year. But the M72/AS01E phase III trial is only part of the story. For the first time, ever, the TB vaccine field is preparing to mount multiple phase III trials of several different vaccine candidates. Collectively, these studies will enroll tens of thousands of people and take place in over a dozen countries. A phase III trial sponsored by the Indian Council of Medical Research—which is evaluating two candidate vaccines called VPM1002 and MIP—is expected to share results sometime in 2023. And next-generation candidates, including the first mRNA-based TB vaccines, are entering early phase I studies.
There’s a lot to pay attention to; and yet, the promising science in the pipeline is threatened by the severe funding shortfall for TB vaccine research and development (R&D). In addition, the future availability and accessibility of new TB vaccines depends on preparations that governments, manufacturers, advocates, and other stakeholders begin making today, while clinical trials are underway, instead of waiting until results are in hand.
Join Treatment Action Group (TAG) for a webinar to learn more about these and other important developments in TB vaccine research. The webinar will provide an overview of the TB vaccine pipeline, based on TAG’s recent Tuberculosis Vaccines Pipeline Report, including the different candidates at different stages of research and ongoing and upcoming studies that advocates should closely follow. This webinar is intended for community, civil society, and other advocates and interested stakeholders. Participants will have an opportunity to ask questions about the pipeline with no specialized knowledge of TB vaccine research assumed.
By better understanding the pipeline, participants will be equipped to advocate for TB vaccines at upcoming events like the UN High-Level Meeting on TB; build demand for new TB vaccines by sharing information with communities; and support governments as they undertake clinical trials and begin preparing for new TB vaccine policymaking and introduction.
A detailed agenda will be shared soon. Get more information about the webinar and register here.